C-reactive protein is a prognostic parameter in patients with cervical cancer

Gynecologic Oncology

Volumn 107, Issue 1, 2007, Pages 114-117

  Polterauer, Stephan ^a   Grimm, Christoph ^a   Tempfer, Clemens ^a   Sliutz, Gerhard ^a   Speiser, Paul ^a   Reinthaller, Alexander ^a   Hefler, Lukas A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cervical cancer; CRP; Prognosis; Serum

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; UTERINE CERVIX CANCER;

C-REACTIVE PROTEIN; FEMALE; HUMANS; LYMPHATIC METASTASIS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 34648832094     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.06.001     Document Type: Article

References (32)

1. Marnell L., Mold C., and Du Clos T.W. C-reactive protein: ligands, receptors and role in inflammation. Clin. Immunol. 117 (2005) 104-111
2. Black S., Kushner I., and Samols D. C-reactive protein. J. Biol. Chem. 279 (2004) 48487-48490
3. Molenaar E.T., Voskuyl A.E., Familian A., van Mierlo G.J., Dijkmans B.A., and Hack C.E. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. Arthritis Rheum. 44 (2001) 997-1002
4. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
5. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
6. Schacter E., and Weitzman S.A. Chronic inflammation and cancer. Oncology 16 (2002) 217-226
7. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
8. McSorley M.A., Alberg A.J., Allen D.S., Allen N.E., Brinton L.A., Dorgan J.F., et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet. Gynecol. 109 (2007) 933-941
9. Erlinger T.P., Platz E.A., Rifai N., and Helzlsouer K.J. C-reactive protein and the risk of incident colorectal cancer. JAMA 291 (2004) 585-590
10. Siemes C., Visser L.E., Coebergh J.W., Splinter T.A., Witteman J.C., Uitterlinden A.G., et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J. Clin. Oncol. 24 (2006) 5216-5222
11. Helzlsouer K.J., Erlinger T.P., and Platz E.A. C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur. J. Cancer 42 (2006) 704-707
12. Zahlten-Hinguranage A., Goldschmidt H., Cremer F.W., Egerer G., Moehler T., Witte D., et al. Preoperative elevation of serum C-reactive protein is predictive for prognosis in myeloma bone disease after surgery. Br. J. Cancer 95 (2006) 782-787
13. Gockel I., Dirksen K., Messow C.M., and Junginger T. Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J. Gastroenterol. 12 (2006) 3746-3750
14. Guillem P., and Triboulet J.P. Elevated serum levels of C-reactive protein are indicative of poor prognosis in patients with esophageal cancer. Dis. Esophagus 18 (2005) 146-150
15. Hashimoto K., Ikeda Y., Korenaga D., Tanoue K., Hamatake M., Kawasaki K., et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103 (2005) 1856-1864
16. Tadahiro N., Takashi M., Masayuki K., and Keizo S. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am. J. Surg. 176 (1998) 335-338
17. Nielsen H.J., Christensen J., Sorensen S., Moesgard F., and Brünner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann. Surg. Oncol. 7 (2000) 617-623
18. Gunter M.J., Stolzenberg-Solomon R., Cross A.J., Leitzmann M.F., Weinstein S., Wood R.J., et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res. 66 (2006) 2483-2487
19. Miyata Y., Koga S., Nishikido M., Noguchi M., Kanda S., Hayashi T., et al. Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 58 (2001) 161-164
20. Lamb G.W.A., McMillan D.C., Ramsey S., and Aitchison M. The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br. J. Cancer 94 (2006) 781-784
21. Jones J.M., McGinogle N.C., McAnespie M., Cran G.W., and Graham A.N. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer 53 (2006) 97-101
22. Brown D.J.F., Milroy R., Preston T., and McMillan D.C. The relationship between an inflammation based prognostic score (GPS) and changes in serum biochemical variables an patients with advanced lung and gastrointestinal cancer. J. Clin. Pathol. (2006 (Apr 27)) [electronic publication ahead of print]
23. Munoz N., Castellsague X., Berrington de Gonzalez A., and Gissmann L. HPV in the aetiology of human cancer. Vaccine 24 (2006) 1-10
24. Kang S., Kim J.W., Park N.H., Song Y.S., Park S.Y., Kang S.B., et al. Interleukin-1 Beta-511 polymorphism and risk of cervical cancer. J. Korean Med. Sci. 22 (2007) 110-113
25. Gocze P.M., Vahrson H.W., and Freeman D.A. Serum levels of squamous cell carcinoma antigen and ovarian carcinoma antigen (CA 125) in patients with benign and malignant diseases of the uterine cervix. Oncology 51 (1994) 430-434
26. Gaarenstroom K.N., Kenter G.G., Bonfrer J.M., Korse C.M., Van de Vijver M.J., Fleuren G.J., et al. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?. Gynecol. Oncol. 77 (2000) 164-170
27. Bolli J.A., Doering D.L., Bosscher J.R., Day Jr. T.G., Rao C.V., Owens K., et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix. Gynecol. Oncol. 55 (1994) 169-173
28. Juang C.M., Wang P.H., Yen M.S., Lai C.R., Ng H.T., and Yuan C.C. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix. Gynecol. Oncol. 76 (2000) 103-106
29. Sproston A.R., Roberts S.A., Davidson S.E., Hunter R.D., and West C.M. Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy. Br. J. Cancer 72 (1995) 1536-1540
30. Fujiwaki R., Iida K., Nakayama K., Kanasaki H., Hata K., Katabuchi H., et al. Clinical significance of interleukin-1 receptor antagonist in patients with cervical carcinoma. Gynecol. Oncol. 89 (2003) 77-83
31. Srivani R., and Nagarajan B. A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int. J. Gynecol. Cancer 13 (2003) 331-339
32. Tartour E., Gey A., Sastre-Garau X., Lombard Surin I., Mosseri V., and Fridman W.H. Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J. Natl. Cancer Inst. 90 (1998) 287-294